Venus Power Ventures (India) Ltd.

BSE

Price on BSE 30 Nov,15:32 LIVE

1.04

-0.05

(-4.59%)

Volume :
250.00

Prev Close :
1.09

Day's H/L (Rs.) :
1.04 - 1.04

52wk H/L (Rs.) :
2.37 - 1.04

Mkt Cap (Rs. Cr) :
1.58

NSE

Venus Power Ventures (India) Ltd. is not listed on NSE

Report Card - Venus Power Ventures (India) Ltd.

PE Ratios

EPS (Rs.)

0.30

Sales (Rs. Cr)

6.25

Face Value (Rs.)

Net Profit Margin(%)

1.50

Last Bonus

Last Dividend(%)

Return on Average Equity

1.95

News for Venus Power Ventures (India) Ltd.

PropShare Celestia IPO Subscribed 1.33 Times

PropShare Celestia's Rs 244-cr IPO subscribed 1.33 times on closing day. Proceeds to acquire floors in Ahmedabad. Details here.

Apr 16, 2026 18:51

Venu Srinivasan Resigns from Tata Trust

Venu Srinivasan resigns from Bai Hirabai Jamsetji Tata Navsari Charitable Institution. Follows challenge from Mehli Mistry.

Apr 04, 2026 20:49

TVS Venu Group Acquires PGIM India Asset Management

TVS Venu Group to acquire PGIM's India asset management business for an undisclosed sum. Deal includes PGIM India Asset Management & Trustees.

Apr 02, 2026 21:42

Hyundai VENUE, Kia Seltos score 5-star BNCAP rating

Hyundai VENUE and Kia Seltos SUVs achieve 5-star safety ratings in BNCAP crash tests. Details on adult and child occupant protection scores.

Mar 30, 2026 17:40

PropShare Celestia IPO Opens April 10

PropShare Celestia's Rs 244.65 cr IPO opens April 10. Invest in SM REIT, Venus Stratum, Ahmedabad. Price band Rs 10-10.50 lakh.

Mar 30, 2026 17:10

More News for Venus Power Ventures (India) Ltd. »

News for Construction

India Real Estate: Capital Inflows Rise 72% to $5.1 Billion

Indian real estate sees record $5.1 billion capital inflow in Jan-Mar, a 72% rise. Developers & REITs drive growth despite global uncertainty.

Apr 22, 2026 11:03

Ajanta Pharma Gets USFDA Form 483 with 5 Observations

USFDA issues Form 483 with five observations to Ajanta Pharma's Paithan facility in Maharashtra after inspection. Company to respond soon.

Apr 22, 2026 10:59

Lupin Launches Anti-Diabetic Tablets in US

Lupin launches generic dapagliflozin and metformin hydrochloride extended-release tablets in the US after USFDA approval.

Apr 22, 2026 10:51

HCLTech Shares Tank After Earnings

HCLTech shares fell nearly 10% after March quarter earnings. FY27 growth guidance is 1-4%. AI revenue crosses $620M.

Apr 22, 2026 10:48

RBI Monitors FDI Outflows, Exchange Rates

RBI Governor Sanjay Malhotra closely monitors short-term fluctuations like FDI outflows and exchange rate movements. India's strong macroeconomic fundamentals highlighted.

Apr 22, 2026 10:48

More News »

Top News

India Real Estate: Capital Inflows Rise 72% to $5.1 Billion

Indian real estate sees record $5.1 billion capital inflow in Jan-Mar, a 72% rise. Developers & REITs drive growth despite global uncertainty.

Apr 22, 2026 11:03

Ajanta Pharma Gets USFDA Form 483 with 5 Observations

USFDA issues Form 483 with five observations to Ajanta Pharma's Paithan facility in Maharashtra after inspection. Company to respond soon.

Apr 22, 2026 10:59

Lupin Launches Anti-Diabetic Tablets in US

Lupin launches generic dapagliflozin and metformin hydrochloride extended-release tablets in the US after USFDA approval.

Apr 22, 2026 10:51

HCLTech Shares Tank After Earnings

HCLTech shares fell nearly 10% after March quarter earnings. FY27 growth guidance is 1-4%. AI revenue crosses $620M.

Apr 22, 2026 10:48

RBI Monitors FDI Outflows, Exchange Rates

RBI Governor Sanjay Malhotra closely monitors short-term fluctuations like FDI outflows and exchange rate movements. India's strong macroeconomic fundamentals highlighted.

Apr 22, 2026 10:48

More Top News »

Sectoral Indices Market Indicators Listed Companies Gainers Losers Mutual Funds Portfolio Watchlist